{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T18:52:10Z","timestamp":1794509530351,"version":"4.9.1"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["75N91019D00024"],"award-info":[{"award-number":["75N91019D00024"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["75N91021F00001"],"award-info":[{"award-number":["75N91021F00001"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005788","name":"Medizinische Universit\u00e4t Wien","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020105","name":"VIVA Foundation for Children with Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020105","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015691","name":"National Institute of Allergy and Infectious Diseases Division of Microbiology and Infectious Diseases","doi-asserted-by":"publisher","award":["75N93023C00019"],"award-info":[{"award-number":["75N93023C00019"]}],"id":[{"id":"10.13039\/100015691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015691","name":"National Institute of Allergy and Infectious Diseases Division of Microbiology and Infectious Diseases","doi-asserted-by":"publisher","award":["U19AI168631"],"award-info":[{"award-number":["U19AI168631"]}],"id":[{"id":"10.13039\/100015691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015691","name":"National Institute of Allergy and Infectious Diseases Division of Microbiology and Infectious Diseases","doi-asserted-by":"publisher","award":["75N93019C00051"],"award-info":[{"award-number":["75N93019C00051"]}],"id":[{"id":"10.13039\/100015691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015691","name":"National Institute of Allergy and Infectious Diseases Division of Microbiology and Infectious Diseases","doi-asserted-by":"publisher","award":["P01 AI172531"],"award-info":[{"award-number":["P01 AI172531"]}],"id":[{"id":"10.13039\/100015691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.vaccine.2025.127602","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T03:03:58Z","timestamp":1755831838000},"page":"127602","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Mucosal COVID-19 vaccines in clinical development"],"prefix":"10.1016","volume":"63","author":[{"given":"Alina","family":"Tscherne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weina","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean T.H.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Krammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2025.127602_bb0005","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41591-022-02138-x","article-title":"Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the omicron wave","volume":"29","author":"Tan","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2025.127602_bb0010","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1186\/s12879-024-09902-z","article-title":"COVID-19 breakthrough infections in vaccinated individuals at BPKIHS","volume":"24","author":"Karmacharya","year":"2024","journal-title":"Nepal BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127602_bb0015","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.vaccine.2024.01.088","article-title":"Infection-mediated immune response in SARS-CoV-2 breakthrough infection and implications for next-generation COVID-19 vaccine development","volume":"42","author":"Miyamoto","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127602_bb0020","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.puhe.2021.02.025","article-title":"Vaccine hesitancy in the era of COVID-19","volume":"194","author":"Troiano","year":"2021","journal-title":"Public Health"},{"key":"10.1016\/j.vaccine.2025.127602_bb0025","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41591-022-02185-4","article-title":"A survey of COVID-19 vaccine acceptance across 23 countries in 2022","volume":"29","author":"Lazarus","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2025.127602_bb0030","doi-asserted-by":"crossref","first-page":"2002083","DOI":"10.1080\/21645515.2021.2002083","article-title":"A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson","volume":"18","author":"Patel","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2025.127602_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103788","article-title":"Mucosal immune response in BNT162b2 COVID-19 vaccine recipients","volume":"75","author":"Azzi","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.vaccine.2025.127602_bb0040","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41385-022-00511-0","article-title":"Systemic and mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection","volume":"15","author":"Sheikh-Mohamed","year":"2022","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.vaccine.2025.127602_bb0045","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02716-22","article-title":"SARS-CoV-2-neutralizing humoral IgA response occurs earlier but is modest and diminishes faster than IgG response","volume":"10","author":"Takamatsu","year":"2022","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.vaccine.2025.127602_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104402","article-title":"SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination","volume":"87","author":"Liew","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.vaccine.2025.127602_bb0055","article-title":"Determinants of SARS-CoV-2 entry and replication in airway mucosal tissue and susceptibility in smokers","volume":"2","author":"Nakayama","year":"2021","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.vaccine.2025.127602_bb0060","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/infdis\/jiae018","article-title":"Compartmentalized SARS-CoV-2 replication in the upper vs lower respiratory tract after intranasal inoculation or aerosol exposure","volume":"230","author":"Fischer","year":"2024","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127602_bb0065","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1146\/annurev-immunol-101320-123742","article-title":"Molecular mechanisms of multimeric assembly of IgM and IgA","volume":"40","author":"Matsumoto","year":"2022","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.vaccine.2025.127602_bb0070","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/infdis\/jiae447","article-title":"Early, robust mucosal secretory immunoglobulin a but not immunoglobulin G response to severe acute respiratory syndrome coronavirus 2 spike in Oral fluid is associated with faster viral clearance and coronavirus disease 2019 symptom resolution","volume":"231","author":"Pisanic","year":"2025","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127602_bb0075","first-page":"11","article-title":"Next generation mucosal vaccine strategy for respiratory pathogens","author":"Dotiwala","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2025.127602_bb0080","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/s41577-021-00583-2","article-title":"Mucosal vaccines - fortifying the frontiers","volume":"22","author":"Lavelle","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2025.127602_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.127356","article-title":"A review of currently licensed mucosal COVID-19 vaccines","volume":"61","author":"Tscherne","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127602_bb0090","first-page":"13","article-title":"Intranasal ChAdOx1 nCoV-19\/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models","author":"van Doremalen","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2025.127602_bb0095","doi-asserted-by":"crossref","first-page":"6592","DOI":"10.1038\/s41467-023-42346-8","article-title":"Infection- or AZD1222 vaccine-mediated immunity reduces SARS-CoV-2 transmission but increases omicron competitiveness in hamsters","volume":"14","author":"Port","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2025.127602_bb0100","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41541-021-00315-6","article-title":"ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets","volume":"6","author":"Marsh","year":"2021","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2025.127602_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104298","article-title":"Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial","volume":"85","author":"Madhavan","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.vaccine.2025.127602_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109401","article-title":"A safe and effective mucosal RSV vaccine in mice consisting of RSV phosphoprotein and flagellin variant","volume":"36","author":"Zhao","year":"2021","journal-title":"Cell Rep"},{"key":"10.1016\/j.vaccine.2025.127602_bb0115","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1093\/jleuko\/qiad030","article-title":"Enhanced TLR5-dependent migration and activation of antigen-loaded airway dendritic cells by flagellin","volume":"113","author":"Li","year":"2023","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.vaccine.2025.127602_bb0120","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s41392-024-01822-3","article-title":"Nasal vaccination of triple-RBD scaffold protein with flagellin elicits long-term protection against SARS-CoV-2 variants including JN.1","volume":"9","author":"Li","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.vaccine.2025.127602_bb0125","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.nbt.2022.08.002","article-title":"An engineered SARS-CoV-2 receptor-binding domain produced in Pichia pastoris as a candidate vaccine antigen","volume":"72","author":"Limonta-Fernandez","year":"2022","journal-title":"New Biotechnol"},{"key":"10.1016\/j.vaccine.2025.127602_bb0130","first-page":"12","article-title":"Safety and immunogenicity of the intranasal vaccine candidate Mambisa and the intramuscular vaccine Abdala used as booster doses for COVID-19 convalescents: a randomized phase 1-2 clinical trial","author":"Lemos-Perez","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2025.127602_bb0135","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/infdis\/jiab561","article-title":"Oral vaccination protects against severe acute respiratory syndrome coronavirus 2 in a Syrian Hamster challenge model","volume":"225","author":"Johnson","year":"2022","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127602_bb0140","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn6868","article-title":"Adenovirus type 5 SARS-CoV-2 vaccines delivered orally or intranasally reduced disease severity and transmission in a hamster model","volume":"14","author":"Langel","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2025.127602_bb0145","doi-asserted-by":"crossref","first-page":"6197","DOI":"10.1038\/s41467-021-26499-y","article-title":"A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses","volume":"12","author":"Sun","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2025.127602_bb0150","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1524477","article-title":"Mucosal multivalent NDV-based vaccine provides cross-reactive immune responses against SARS-CoV-2 variants in animal models","volume":"16","author":"Gonzalez-Dominguez","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.127602_bb0155","article-title":"Safety and immunogenicity of a Newcastle disease virus vector-based SARS-CoV-2 vaccine candidate, AVX\/COVID-12-HEXAPRO (patria)","volume":"12","author":"Lara-Puente","year":"2021","journal-title":"Pigs mBio"},{"key":"10.1016\/j.vaccine.2025.127602_bb0160","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41541-023-00662-6","article-title":"Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico","volume":"8","author":"Ponce-de-Leon","year":"2023","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2025.127602_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2024.126511","article-title":"Phase II study on the safety and immunogenicity of single-dose intramuscular or intranasal administration of the AVX\/COVID-12 \u201cpatria\u201d recombinant Newcastle disease virus vaccine as a heterologous booster against COVID-19 in Mexico","volume":"43","author":"Lopez-Macias","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127602_bb0170","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s41392-023-01423-6","article-title":"Intranasal booster using an omicron vaccine confers broad mucosal and systemic immunity against SARS-CoV-2 variants","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.vaccine.2025.127602_bb0175","first-page":"9","article-title":"An intranasally administered adenovirus-vectored SARS-CoV-2 vaccine induces robust mucosal secretory IgA","author":"Sun","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.vaccine.2025.127602_bb0180","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/s41392-024-01906-0","article-title":"Intranasal adenovirus-vectored omicron vaccine induced nasal immunoglobulin a has superior neutralizing potency than serum antibodies","volume":"9","author":"Chen","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"896\u2013915","key":"10.1016\/j.vaccine.2025.127602_bb0185","article-title":"Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2","volume":"185","author":"Afkhami","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2025.127602_bb0190","doi-asserted-by":"crossref","first-page":"6000","DOI":"10.1038\/s41467-025-60726-0","article-title":"Induction of lung mucosal immunity by a next-generation inhaled aerosol COVID-19 vaccine: an open-label, multi-arm phase 1 clinical trial","volume":"16","author":"Jeyanathan","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2025.127602_bb0195","first-page":"7","article-title":"Protection of K18-hACE2 mice and ferrets against SARS-CoV-2 challenge by a single-dose mucosal immunization with a parainfluenza virus 5-based COVID-19 vaccine","author":"An","year":"2021","journal-title":"Sci Adv"},{"key":"10.1016\/j.vaccine.2025.127602_bb0200","doi-asserted-by":"crossref","first-page":"eadw0896","DOI":"10.1126\/sciadv.adw0896","article-title":"Safety and immunogenicity of intranasal parainfluenza virus type 5 (PIV5)-vectored COVID-19 vaccine in adults and teens in an open-label phase 1 trial","volume":"11","author":"Spearman","year":"2025","journal-title":"Sci Adv"},{"key":"10.1016\/j.vaccine.2025.127602_bb0205","doi-asserted-by":"crossref","DOI":"10.3390\/molecules28134996","article-title":"Creating a vaccine-like supplement against respiratory infection using recombinant Bacillus subtilis spores expressing SARS-CoV-2 spike protein with natural products","volume":"28","author":"Chan","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.vaccine.2025.127602_bb0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1142\/S0192415X16500014","article-title":"Astragalus membranaceus: a review of its protection against inflammation and gastrointestinal cancers","volume":"44","author":"Auyeung","year":"2016","journal-title":"Am J Chin Med"},{"key":"10.1016\/j.vaccine.2025.127602_bb0215","doi-asserted-by":"crossref","first-page":"78","DOI":"10.2174\/187221312798889310","article-title":"Efficacy of Yun Zhi (Coriolus versicolor) on survival in cancer patients: systematic review and meta-analysis","volume":"6","author":"Eliza","year":"2012","journal-title":"Recent Patents Inflamm Allergy Drug Discov"},{"key":"10.1016\/j.vaccine.2025.127602_bb0220","first-page":"10","article-title":"Safety and immunogenicity of inactivated Bacillus subtilis spores as a heterologous antibody booster for COVID-19 vaccines","author":"Sung","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2025.127602_bb0240","article-title":"Scalable live-attenuated SARS-CoV-2 vaccine candidate demonstrates preclinical safety and efficacy","volume":"118","author":"Wang","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2025.127602_bb0245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1011057","article-title":"Live-attenuated pediatric parainfluenza vaccine expressing 6P-stabilized SARS-CoV-2 spike protein is protective against SARS-CoV-2 variants in hamsters","volume":"19","author":"Liu","year":"2023","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2025.127602_bb0250","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41541-022-00509-6","article-title":"Mucosal administration of a live attenuated recombinant COVID-19 vaccine protects nonhuman primates from SARS-CoV-2","volume":"7","author":"Tioni","year":"2022","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2025.127602_bb0255","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1038\/s41467-024-47784-6","article-title":"Mucosal prime-boost immunization with live murine pneumonia virus-vectored SARS-CoV-2 vaccine is protective in macaques","volume":"15","author":"Kaiser","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2025.127602_bb0260","first-page":"9","article-title":"Single-dose intranasal administration of AdCOVID elicits systemic and mucosal immunity against SARS-CoV-2 and fully protects mice from lethal challenge","author":"King","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2025.127602_bb0265","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-94364-5","article-title":"Intranasal plus subcutaneous prime vaccination with a dual antigen COVID-19 vaccine elicits T-cell and antibody responses in mice","volume":"11","author":"Rice","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2025.127602_bb0270","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.729837","article-title":"Dual-antigen COVID-19 vaccine subcutaneous prime delivery with Oral boosts protects NHP against SARS-CoV-2 challenge","volume":"12","author":"Gabitzsch","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.127602_bb0275","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abm8563","article-title":"Comparison of replicating and nonreplicating vaccines against SARS-CoV-2","volume":"8","author":"Mudrick","year":"2022","journal-title":"Sci Adv"},{"key":"10.1016\/j.vaccine.2025.127602_bb0280","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.781280","article-title":"An intranasal OMV-based vaccine induces high mucosal and systemic protecting immunity against a SARS-CoV-2 infection","volume":"12","author":"van der Ley","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.127602_bb0285","doi-asserted-by":"crossref","first-page":"16757","DOI":"10.1021\/acsnano.2c06350","article-title":"Artificial cell membrane Polymersome-based intranasal Beta spike formulation as a second generation Covid-19 vaccine","volume":"16","author":"Lam","year":"2022","journal-title":"ACS Nano"},{"key":"10.1016\/j.vaccine.2025.127602_bb0290","doi-asserted-by":"crossref","first-page":"1588259","DOI":"10.3389\/fimmu.2025.1588259","article-title":"The immunological impact of revaccination in a hybrid-immune world","volume":"16","author":"Bausch-Jurken","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.127602_bb0295","first-page":"12","article-title":"Hybrid immunity against SARS-CoV-2 variants: a narrative review of the literature","author":"Tsagkli","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2025.127602_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.127175","article-title":"Mucosal immune responses to SARS-CoV-2 infection and COVID-19 vaccination","volume":"56","author":"Paul","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127602_bb0305","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/B978-0-323-39981-4.00015-4","article-title":"Nasal Vaccine Delivery","author":"Ramvikas","year":"2017","journal-title":"Micro and Nanotechnology in Vaccine Development"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2025.127602_bb0310","first-page":"13","article-title":"Nasal mucociliary clearance as a factor in nasal drug delivery","volume":"29","author":"Merkus","year":"1998","journal-title":"Adv Drug Deliv Rev."},{"key":"10.1016\/j.vaccine.2025.127602_bb0315","first-page":"10","article-title":"What is the predictive value of animal models for vaccine efficacy in humans? The importance of bridging studies and species-independent correlates of protection","author":"Golding","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.vaccine.2025.127602_bb0320","series-title":"Innovation in vaccinology: From design, through to delivery and testing","first-page":"251","article-title":"The importance of animal models in the development of vaccines","author":"Kiros","year":"2012"},{"key":"10.1016\/j.vaccine.2025.127602_bb0325","doi-asserted-by":"crossref","first-page":"7225","DOI":"10.1038\/s41467-024-51535-y","article-title":"A single-dose intranasal live-attenuated codon deoptimized vaccine provides broad protection against SARS-CoV-2 and its variants","volume":"15","author":"Liu","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2025.127602_bb0330","series-title":"Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19","author":"Ocugen","year":"2025"},{"key":"10.1016\/j.vaccine.2025.127602_bb0335","series-title":"Game-changing needle-free COVID-19 intranasal vaccine","author":"Griffith University","year":"2024"},{"key":"10.1016\/j.vaccine.2025.127602_bb0340","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2127292","article-title":"A single intranasal administration of AdCOVID protects against SARS-CoV-2 infection in the upper and lower respiratory tracts","volume":"18","author":"Schultz","year":"2022","journal-title":"Hum Vaccin Immunother"},{"issue":"4811\u201325","key":"10.1016\/j.vaccine.2025.127602_bb0345","article-title":"Intranasal pediatric parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in monkeys","volume":"185","author":"Le Nouen","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2025.127602_bb0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104585","article-title":"Mucosal vaccines for SARS-CoV-2: triumph of hope over experience","volume":"92","author":"Pilapitiya","year":"2023","journal-title":"EBioMedicine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25008990?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25008990?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T04:48:32Z","timestamp":1779770912000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25008990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":67,"alternative-id":["S0264410X25008990"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127602","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mucosal COVID-19 vaccines in clinical development","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127602","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"127602"}}